Chimeric Halts CAR T-cell Trial Enrollment, Shifts Approach
August 24, 2026
CDH17 Remains a Promising Target, Even as the CHM CDH17 Trial Changes Course The CHM
$42.8M
 in neuroendocrine cancer research funding
171
Funded Research
Projects
17
Countries with ongoing studies
CDH17 Remains a Promising Target, Even as the CHM CDH17 Trial Changes Course The CHM
The Neuroendocrine Tumor Research Foundation (NETRF) is deeply grateful to Citizens of Humanity for donating
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Same organ, different disease Words matter
You can support a brighter future. Make a gift. Host an event. Or volunteer to help us advance our understanding of neuroendocrine cancer.
Learn about neuroendocrine cancer tests, treatments, and research. Find out about educational and inspirational events in the neuroendocrine cancer community.
NETRF hosts free patient and caregiver neuroendocrine cancer conferences to educate and empower individuals to be part of their care planning and live their best life.